Ipamorelin vs Tesamorelin
A comprehensive, data-driven comparison of Ipamorelin (NNC 26-0161) and Tesamorelin (Egrifta). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Ipamorelin NNC 26-0161 | Tesamorelin Egrifta, TH9507 |
|---|---|---|
| FDA Status | Category 2 (pending reclassification) | FDA Approved |
| Category | Growth Hormone | Growth Hormone |
| Primary Use | Growth hormone optimization | HIV-associated lipodystrophy |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $35 - $70/mo | $200 - $1,500/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 200-300mcg 2-3x daily | 2mg daily |
| Frequency | Daily | Daily |
| Mechanism | Selective growth hormone secretagogue that binds to ghrelin receptors to stimulate GH release without affecting cortisol or prolactin | Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone production |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Emerging | High |
| Clinical Trial Phase | N/A | Approved |
Key Differences
- 1Tesamorelin is FDA-approved, while Ipamorelin is currently category 2 (pending reclassification).
- 2Ipamorelin is generally more affordable ($35 - $70/mo) compared to Tesamorelin ($200 - $1,500/mo).
- 3Tesamorelin has high-quality evidence, while Ipamorelin has emerging-quality evidence.
Which Is Better For...
Tesamorelin
Those seeking an FDA-approved treatment with established safety data
Ipamorelin
More budget-friendly option with lower monthly costs
Ipamorelin
Fewer commonly reported side effects
Tesamorelin
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Ipamorelin | $35 - $70/mo | Category 2 (pending reclassification) | Various research labs |
| Tesamorelin | $200 - $1,500/mo | FDA Approved | Theratechnologies |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Ipamorelin works via Selective growth hormone secretagogue that binds to ghrelin receptors to stimulate GH. Tesamorelin works via Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone. They differ in FDA approval status, efficacy data, and cost.
Ipamorelin typically costs $35 - $70/mo, while Tesamorelin costs $200 - $1,500/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Ipamorelin is not FDA-approved (Category 2 (pending reclassification)). Tesamorelin is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Ipamorelin include Injection site reactions, Increased hunger, Headache. Common side effects of Tesamorelin include Injection site reactions, Arthralgia, Peripheral edema. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Ipamorelin is a pentapeptide that selectively stimulates growth hormone release by mimicking ghrelin, the hunger hormone. Unlike many other GH secretagogues, ipamorelin does not significantly increase...
View Full Ipamorelin GuideTesamorelin is an FDA-approved synthetic growth hormone releasing hormone analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. A new weekly reco...
View Full Tesamorelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Ipamorelin and Tesamorelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.